» Articles » PMID: 36291336

Current Perspectives on Pharmacological and Non-Pharmacological Interventions for the Inflammatory Mechanism of Unipolar Depression

Overview
Journal Brain Sci
Publisher MDPI
Date 2022 Oct 27
PMID 36291336
Authors
Affiliations
Soon will be listed here.
Abstract

Since depression remains a major public health issue there is a constant need for new and more efficient therapeutic strategies based on the mechanisms involved in the aetiology of depression. Thus, the pathogenic link between depression and inflammation is considered to play a potential key role in the development of such therapies. This review summarizes the results of various pharmacological (non-steroidal anti-inflammatory drugs, aspirin, cyclooxygenase inhibitors, cytokine inhibitors, corticosteroids, statins, minocycline, N-acetyl cysteine, omega-3 fatty acids and probiotics) and non-pharmacological interventions (electroconvulsive therapy, physical exercise and psychological therapy) and outlines their efficacy and discusses potential challenges. Both conventional and non-conventional anti-inflammatory drugs showed promising results according to the specific group of patients. The pre-existing pro-inflammatory status was, in most cases, a predictor for clinical efficacy and, in some cases, a correlation between clinical improvement and changes in various biomarkers was found. Some of the non-pharmacological interventions (physical exercise and electroconvulsive therapy) have also showed beneficial effects for depressive patients with elevated inflammatory markers. Treatments with anti-inflammatory action may improve clinical outcomes in depression, at least for some categories of patients, thus opening the way for a future personalised approach to patients with unipolar depression regarding the inflammation-related mechanism.

Citing Articles

Predictive Value of Inflammatory Biomarkers in Assessing Major Depression in Adults.

Gavril R, Dobrin P, Pinzariu A, Moscalu M, Grigore R, Iacob V Biomedicines. 2024; 12(11).

PMID: 39595067 PMC: 11591788. DOI: 10.3390/biomedicines12112501.


3D Simulation-Driven Design of a Microfluidic Immunosensor for Real-Time Monitoring of Sweat Biomarkers.

Jebari N, Dufour-Gergam E, Ammar M Micromachines (Basel). 2024; 15(8).

PMID: 39203587 PMC: 11356042. DOI: 10.3390/mi15080936.


Omega-3 PUFAs' efficacy in the therapy of coronary artery disease combined with anxiety or depression: a meta-analysis.

Gui Y, He D, Li J, Zhao H Front Psychiatry. 2024; 15:1368007.

PMID: 38979505 PMC: 11228296. DOI: 10.3389/fpsyt.2024.1368007.


Gut Microbiota Dysbiosis and Inflammation Dysfunction in Late-Life Depression: An Observational Cross-Sectional Analysis.

Chen Y, Le D, Xu J, Jin P, Zhang Y, Liao Z Neuropsychiatr Dis Treat. 2024; 20:399-414.

PMID: 38436041 PMC: 10908248. DOI: 10.2147/NDT.S449224.


Electroacupuncture versus Escitalopram for mild to moderate Post-Stroke Depression: A randomized non-inferiority trial.

Ma F, Cao G, Lu L, Zhu Y, Li W, Chen L Front Psychiatry. 2024; 15:1332107.

PMID: 38370556 PMC: 10869574. DOI: 10.3389/fpsyt.2024.1332107.


References
1.
Kim S, Bae K, Kim J, Shin I, Hong Y, Ahn Y . The use of statins for the treatment of depression in patients with acute coronary syndrome. Transl Psychiatry. 2015; 5:e620. PMC: 4564569. DOI: 10.1038/tp.2015.116. View

2.
Yatham M, Yatham K, Ravindran A, Sullivan F . Do statins have an effect on depressive symptoms? A systematic review and meta-analysis. J Affect Disord. 2019; 257:55-63. DOI: 10.1016/j.jad.2019.07.002. View

3.
Strawbridge R, Hodsoll J, Powell T, Hotopf M, Hatch S, Breen G . Inflammatory profiles of severe treatment-resistant depression. J Affect Disord. 2018; 246:42-51. DOI: 10.1016/j.jad.2018.12.037. View

4.
Park C, Brietzke E, Rosenblat J, Musial N, Zuckerman H, Ragguett R . Probiotics for the treatment of depressive symptoms: An anti-inflammatory mechanism?. Brain Behav Immun. 2018; 73:115-124. DOI: 10.1016/j.bbi.2018.07.006. View

5.
Langley R, Feldman S, Han C, Schenkel B, Szapary P, Hsu M . Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010; 63(3):457-65. DOI: 10.1016/j.jaad.2009.09.014. View